Bevacizumab as an adjunct to vitreoretinal surgery for diabetic retinopathy in East Africa

Eye (Basingstoke)

Volumn 27, Issue 11, 2013, Pages 1263-1268

  Guthrie, G ^a,b,c   Hall, A B ^c   Dhalla, K ^c   Davis, R M ^a   Steel, D H ^b,d  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c KILIMANJARO CHRISTIAN MEDICAL CENTRE   (Tanzania)

^d SUNDERLAND EYE INFIRMARY   (United Kingdom)

Author keywords

avastin; bevacizumab; diabetic vitrectomy; intravitreal injection; sub Saharan Africa; tractional retinal detachment

Indexed keywords

BEVACIZUMAB; SILICONE OIL;

ADULT; AFRICA; AGED; ARTICLE; CONTROLLED STUDY; DIABETIC RETINOPATHY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; NUMBERS NEEDED TO TREAT; REOPERATION; RETINA DETACHMENT; VISUAL ACUITY; VITREORETINAL SURGERY; VITREOUS HEMORRHAGE;

ADULT; AFRICA, EASTERN; AGED; ANALYSIS OF VARIANCE; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CASE-CONTROL STUDIES; CHEMOTHERAPY, ADJUVANT; DIABETIC RETINOPATHY; FEMALE; HUMANS; INTRAOPERATIVE COMPLICATIONS; MALE; MIDDLE AGED; PREOPERATIVE PERIOD; REOPERATION; RETINAL DETACHMENT; RETROSPECTIVE STUDIES; VISUAL ACUITY; VITREORETINAL SURGERY; VITREOUS HEMORRHAGE; YOUNG ADULT;

EID: 84887815312     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2013.182     Document Type: Article

References (13)

1. International Diabetes Federation. Diabetes Atlas. 5th edn. International Diabetes Federation: Brussels, 2012.
2. Lewallen S, Courtright P. Blindness in Africa: Present situation and future needs. Br J Ophthalmol 2001; 85: 897-903.
3. Avery R, Pearlman J, Pieramici D, Rabena MD, Castellarin AA, Nasir MA et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006; 113: 1695-1705.
4. Mason JI, Nixon P, White M. Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy. Ophthalmology 2006; 142: 685-688.
5. Zhao L-Q, Zhu H, Zhao P, Hu Y. A systematic review and meta-analysis of clinical outcomes of vitrectomy with or without intravitreal bevacizumab pretreatment for severe diabetic retinopathy. Br J Ophthalmol 2011; 95: 1216-1222.
6. Yeh P, Yang C, Lin Y, Chen MS, Yang CH. Bevacizumab pretreatment in vitrectomy with silicone oil for severe diabetic retinopathy. Retina 2009; 29: 768-774.
7. di Lauro R, De Ruggiero P, di Lauro R, di Lauro MT, Romano MR. Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 2010; 248: 785-791.
8. Pokroy R, Desai UR, Du E, Li Y, Edwards P. Bevacizumab prior to vitrectomy for diabetic traction retinal detachment. Eye 2011; 25: 989-997.
9. Schulze-Bonsel K, Feltgen F, Burau H, Hansen L, Bach M. Visual acuities ''hand motion'' and ''counting fingers'' can be quantified with the Freiburg Visual Acuity Test. Invest Ophthalmol Vis Sci 2006; 47: 1236-1240.
10. Da R, Lucena D, Ribeiro JA, Costa RA, Barbosa JC, Scott IU, de Figueiredo-Pontes LL et al. Intraoperative bleeding during vitrectomy for diabetic tractional retinal detachment with versus without preoperative intravitreal bevacizumab (IBeTra Study). Br J Ophthalmol 2009; 93: 688-691.
11. Yorston D, Wickham L, Benson S, Bunce C, Sheard R, Charteris D. Predictive clinical features and outcomes of vitrectomy for proliferative dic retinopathy. Br J Ophthalmol 2008; 92: 365-368.
12. Zhang X, Saaddine JB, Chou CF, Cotch MF, Cheng YJ, Geiss LS et al. Prevalence of diabetic retinopathy in the United States, 2005-2008. JAMA 2010; 304: 649-656.
13. Lewallen S, Mousa A, Bassett K, Courtright P. Cataract surgical coverage remains lower in women. Br J Ophthalmol 2009; 93: 295-298.